Compass Biotechnologies Inc., of Edmonton, Alberta, formed four operational divisions to develop and commercialize products in women's reproductive health; hepatitis antiviral drugs and prophylactic vaccines; recombinant protein therapeutics called biobetters; and cytokine reagents, diagnostics and growth factor supplements for the cell culture and biotech manufacturing industries. The company said it engaged advisors to raise approximately $5 million as a bridge financing in the first quarter of 2012, with a larger secondary offering expected later in the year.